AMANO ENZYME EUROPE LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Deloitte LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Company has experienced a reduction in its cash balance during the year which was due to a change in its business model and the purchase of stock. Cash flow forecasts through to 31 December 2026 were prepared and considered. These indicated that there are no expected shortfalls or potential problems. Therefore, the directors have a reasonable expectation that the Company will continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.”

Significant events

• “Several major projects in the medical sector did not materialise during the year, however, this was partly offset by a steady growth of the existing plant-based business. The delayed projects are expected to materialise in late 2025 and 2026.”
• “The Company has experienced a reduction in its cash balance during the year which was due to a change in its business model and the purchase of stock.”
• “The Company is currently not experiencing any adverse effects arising from the conflicts in Ukraine or the Middle East other than the general impact of higher energy prices, fuel prices and lead time of sea shipments.”
• “The Company's sales have decreased by 14% over the prior year (2023: increased by 3%). This was anticipated in the 2024 budget and is due to the move of some customers to other group companies and a delay in medical projects. The growth in plant-based business remains steady.”
• “The net cash outflow for the year amounted to £3,821,676 in 2024 (2023: net cash inflow of £1,839,147). The net cash outflow includes the settlement for inventory of £2,110,732 (2023: nil). This was a one-off cash outflow to reflect the change of business model.”
• “In 2024, Company incurred a loss on exchange of £200,253 (2023 – loss of £225,832).”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -13.9%

  £33,821,807 → £29,121,634

  lowest in 3 filed years

• Cash

  -43.1%

  £8,860,017 → £5,038,341

• Net assets

  +10.7%

  £6,690,733 → £7,404,487

• Employees

  +31.3%

  16 → 21

  highest in 3 filed years

• Operating profit

  +29.4%

  £741,029 → £958,540

  highest in 3 filed years

• Profit before tax

  +28.5%

  £743,473 → £955,702

• Wages

  +19.4%

  £1,106,751 → £1,321,298

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers